The selective Akt inhibitor, MK-2206, restored GC-induced NR3C1 nuclear translocation and reversed the response of PTEN-null T-ALL cells to GCs in vitro and in vivo. Here, NR3C1 is linked to acute lymphoblastic leukemia.